US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Positive results of first-in-human clinical trial of PreciseInhale now published in European Journal of Pharmaceutical Sciences

(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system PreciseInhale® are now published in a peer-reviewed paper in the European Journal of Pharmaceutical Sciences. The results demonstrate that PreciseInhale® provides greater precision and control than aerosol dosing carried out with a standard commercial inhaler, and can be used for ‘regional targeting’, exposing specific regions of the lungs to a targeted aerosol. The topline results were first communicated on December 20, 2021.The paper is titled Regional lung

Inhalation Sciences’ PreciseInhale receives extended international Registered Trademark

(Stockholm, 10 February 2021) PreciseInhale[®], Inhalation Sciences’ flagship high-precision aerosol generator for preclinical respiratory research, has received an extended international Registered Trademark from the International Bureau of the World Intellectual Property Organization (WIPO). ISAB CEO Manoush Masarrat: “This will play an important role in protection of our trademark and driving the growth of PreciseInhale[®] in many strategic global markets.”The new trademark will last for ten years and designates PreciseInhale[®] as unique and protected not only in the European market –

Inhalation Sciences technology spotlighted by researchers at 4 major industry events

From Austria to Sweden to California to the UK: October has been an intensive month for Inhalation Sciences' flagship aerosol generator PreciseInhale. It has been spotlighted by senior ISAB clients such as Fraunhofer ITEM at four global industry events. “Customers of this calibre sharing the findings they’re achieving really underlines the strategic value we deliver” says ISAB CEO Manoush Masarrat.PreciseInhale has been presented at four different inhalation events in October, each time by clients showcasing specific benefits and findings they got from the system. “The range of events

Inhalation Sciences' PreciseInhale delivers exceptional precision in ground-breaking inhalable nicotine study

September 24, Stockholm, Sweden. In a ground-breaking publication on inhalable nicotine PreciseInhale aerosol technology revealed new data on the drug’s pharmacokinetic behavior that until now was unobtainable. ISAB CEO Manoush Masarrat: “The strategic value of data of this precision is immense. It enables drug developers to establish a failsafe strategy for their inhaled medications from day one.”The preclinical study, by Philip Morris International, analyzed and measured the Pharmacokinetics of two formulations of dry powder nicotine intended for inhalation delivery. As a water-soluble

Inhalation Sciences to conduct 1 MSEK CRO study for major European pharma company

(Stockholm August 5, 2019) Inhalation Sciences (ISAB) is conducting a Contract Research Order feasibility study worth 1 MSEK for a leading European inhaled pharmaceutical developer. ISAB was chosen because of its unique ability to deliver predictive, voluminous data from tiny amounts of challenging substance in nebulized as well as dry powder aerosol.“Few tests are more crucial in an inhaled drug’s lifetime than pre-clinical feasibility studies” says ISAB CEO Lena Heffler. “With a typical drug costing on average 2.6 BUSD to develop, being able to minimize errors and generate predictive data

Inhalation Sciences AB and Clinical Trial Consultants AB collaborate on clinical validation of PreciseInhale

STOCKHOLM, SWEDEN – July 1, 2019. Inhalation Sciences AB (ISAB) has contracted Swedish CRO Clinical Trials Consultants AB to carry out its clinical study validating PreciseInhale for clinical use. CTC CEO Anders Millerhovf: “For us this is a win-win. As an innovation-focussed CRO we appreciate the new value and data that a clinically validated PreciseInhale system will offer the inhalation industry and we look forward to continuing to explore PreciseInhale’s highly competitive capabilities”.ISAB has chosen Swedish CRO CTC to carry out a 15-month study to validate PreciseInhale, its flagship

Another major sale, plus 2 systems shipped in 2 months, CEO speaks

Inhalation Sciences’ recent announcement of a 2 MSEK order from a leading inhalation company is the third major order announced since the appointment of Lena Heffler as new CEO, on May 7. How does she see the year ahead for ISAB? And how will it keep up the momentum?Since starting as ISAB’s new CEO on May 7 Lena Heffler has brought three major orders into the company, including ISAB’s first shipment to China. When appointed CEO she stated: "Inhalation Sciences is in an exciting phase, with many customer dialogues ongoing and a commercial breakthrough within reach.” How does she feel about

Inhalation Sciences to present at Redeye Life Science Day, November 21 Stockholm

Inhalation Sciences’ CEO Lena Heffler’s presentation will also be streamed live. “The world-leading control and precision of our technology means lung scientists save crucial time and money in essential early-stage research. I look forward to showing investors how far we’ve already come.”The event will take place at Haymarket by Scandic, Hötorget in central Stockholm. Lena Heffler’s presentation will be in Sal 2, 08.20-08.40. All presentations at Redeye Life Science Day will be streamed live, beginning at 08.10. They can be followed on smartphone or computer at www.redeye.se/live/lsday-

Inhalation Sciences helps leading research on breathing in metal nanoparticles: Will dissolution testing become mandatory?

More industrial processes than ever are using nanoparticle. Yet many questions remain about the health consequences of inhaling them. Not just in our lungs but at a cellular, even genetic level.  Karolinska Institutet doctoral researcher Sarah Mccarrick is using Inhalation Sciences equipment to test how copper and copper oxide nanoparticles impact us.Nanoparticles offer a world of advantages to industrial process manufacturers. But what happens when we breathe them in? Inhalation researcher Sarah Mccarrick has joined the Institute of Environmental Medicine team at Karolinska Institutet,

Inhalation Sciences Third Quarter Report 2018

Summary of Interim Report, first nine months 2018: Orders were received during the third quarter for PreciseInhale and CRO assignments totalling more than 5 MSEK, a record for the company in a single quarter. During the reporting period the subsidiary Ziccum carried out a successful listing process, which after the end of the quarter resulted in a share issue which raised 15.8 MSEK and was listed on Spotlight Stock Market. Earlier in the year Lena Heffler succeeded Fredrik Sjövall as new CEO, the European Patent Office EPO gave approval notice on one of Inhalation Sciences’ most important

Inhalation Sciences' news roundup: 2.4 MSEK  sale, new patent, upcoming China installation

With a major 2.4 MSEK sale, a new European patent and the upcoming installation of ISAB's first PreciseInhale system in China - September and October have been eventful and dynamic for Sweden's inhalation R&D innovators.ZICCUM AB SHARE ISSUE OVERSUBSCRIBED 234% before listing on Spotlight ISAB spinout company Ziccum attracted 1,000 new shareholders ahead of its listing on Spotlight. Ziccum's technology can formulate liquid biologic therapies and vaccines - as dry powders. Making them more cost-effective and easy-to-transport. CEO Göran Conradson: "It's gratifying that the new issue has

Inhalation Sciences receive European Patent for XposeALI 3D in vitro cell culturing module

Stockholm, Sweden 8 October: The European Patent Office has granted a patent to XposeALI, ISAB’s in vitro cell culturing module. “XposeALI delivers exceptionally precise, detailed data on how airborne micro- and nanoparticles particles affect cells in the lung, early on—whilst dramatically reducing the number of animals needed in research,” says ISAB CEO Lena Heffler.XposeALI is PreciseInhale’s 3D cell exposure module. It’s one of a range of modules, in vitro and in vivo, that can be attached to ISAB’s aerosol generator, PreciseInhale to enable control and precision through all stages of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe